Bortezomib, Rituximab, and Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Relapsed or Refractory Low-Grade, Follicular, or Mantle Cell Non-Hodgkin's Lymphoma

You may be eligible if

• DISEASE CHARACTERISTICS:
• Histologically confirmed low-grade, follicular B-cell, or mantle cell non-Hodgkin's lymphoma
• * Bone marrow biopsy required for pretreatment evaluation
• * Unilateral bone marrow biopsy allowed
• * Core biopsies allowed if they contain adequate tissue for primary diagnosis and immunophenotyping
• Relapsed or refractory disease as defined by disease progression after initial complete response (CR) or failure to achieve CR
• No bone marrow involvement ≥ 25% within the past 30 days
• No pleural effusion or significant ascites
• No active CNS involvement
• PATIENT CHARACTERISTICS:
• ECOG performance status 0-2
• Life expectancy ≥ 3 months
• Platelet count ≥ 100,000/mm\^3
• Absolute neutrophil count ≥ 1,500/mm\^3
• AST ≤ 2.5 times upper limit of normal (ULN)
• Total bilirubin ≤ 2.5 times ULN
• Creatinine clearance ≥ 50 mL/min
• Not pregnant or nursing
• Negative pregnancy test
• Fertile patients must use effective contraception
• Hepatitis B surface antigen negative
• No current infection with hepatitis B virus
• No HIV positivity
• No neuropathy or neuropathic pain ≥ grade 2
• No history of allergic reaction to boron or mannitol
• No active serious infection or medical or psychiatric illness that would preclude study therapy
• No other malignancy within the past 5 years except for the following:
• * Basal cell or squamous cell carcinoma of the skin that has been completely resected
• * In situ malignancy that has been completely resected
• * T1-T2a, N0, M0 prostate cancer treated with a prostatectomy or radiotherapy within the past 2 years with an undetectable PSA level
• No other condition, including any of the following:
• * Myocardial infarction within the past 6 months
• * New York Heart Association class III-IV heart failure
• * Uncontrolled angina
• * Severe uncontrolled ventricular arrhythmias
• * Electrocardiographic evidence of acute ischemia or active conduction system abnormalities
• PRIOR CONCURRENT THERAPY:
• Recovered from all prior therapy
• More than 3 weeks since prior chemotherapy (6 weeks for nitrosoureas or mitomycin C), radiotherapy, or surgical resection of malignancy
• * No limitations on the number of prior therapies
• More than 4 weeks since prior major surgery
• More than 14 days since prior filgrastim (G-CSF) or sargramostim (GM-CSF)
• More than 14 days since prior and no other concurrent investigational agents
• * Concurrent participation in a nontreatment study allowed
• No prior radioimmunotherapy